CA-TRANSPHORM-INC
Transphorm Inc. —the leader in the design and manufacturing of the highest reliability and first JEDEC and AEC-Q101 qualified high voltage gallium nitride (GaN) power semiconductors—today confirmed that customer AES Aircraft Elektro/Elektronik System GmbH has released its first 650 V GaN-based power supplies. Serving the aviation industry, AES supports customers with various products and services ranging from electrical engineering to certification and testing. The company’s newest Switch Mode Power Supplies are currently used by large CS-25 airplane manufacturers (e.g., Airbus A318-A321, A330, A340, A380 and Boeing B767, B787 VIP aircraft) and use Transphorm’s GaN FETs to increase overall system efficiency by more than 10 percent compared to competitive Silicon-based power supply units (PSUs).
The two GaN-based Switch Mode Power Supplies are the PS250X 500 W system and the PS6120 1200 W system . Both products support a 96-130 VAC/360 Hz – 800 Hz input voltage with a 28 VDC continuous power output at 15 amps for the 500 W system and 42 amps for the 1200 W system.
Further, AES certified the PS250X and PS6120 as DO-160 compliant—meeting the more than 25-point stringent Standard of the Radio Technical Commission for Aeronautics (RTCA). This Standard assesses system impact and performance under various external and internal conditions on aircraft—ranging from pressure and temperature to voltage spikes and RF emissions.
The flagship 500 W PS250X is the industry’s first passively cooled power supply at 420 W and deploys Transphorm’s GaN in a single-phase CCM boost power factor correction (PFC) topology. It offers more than 92 percent overall system efficiency at full load, which is more than 10 percent greater than its competition. The system also yields a more than .98 power factor and 200 mVpp nominal at 115 VAC/400 Hz input at full load. All within an end product that is 1.4 kg (~3 lbs).
The 1200 W PS6120 deploys Transphorm’s GaN in a fan-cooled, three-phase CCM boost PFC topology. It offers more than 91.5 percent overall system efficiency at full load, which is 11.5 percent greater than its competition. The PS6120 also yields the same power factor and nominal ripple voltage at 115 VAC/400 Hz input at full load as the PS250X 500 W PSU. All within an end product that is 4.0 kg (~8.8 lbs).
“The aviation industry is working toward reducing climate impact through any means possible,” said Dr. Andreas Hammer, Head of Competence Center Power, AES. “Considering, we sought out Transphorm’s GaN to replace previously used Silicon MOSFETs so that we could provide a more efficient, lighter weight power supply. These supplies have the potential to make a notable impact when considering each aircraft deploys several such PSUs. After only a year of redesign, we were able to offer our customers a better power solution, while also raising the performance bar within our own industry.”
The GaN Selection Process
Interested in the technology’s inherent higher switching frequency, AES reviewed GaN power switch converters from several GaN device semiconductor manufacturers. The company ultimately selected Transphorm’s 650 V GaN technology due primarily to its ease of drivability and designability—specifically because Transphorm’s GaN FETs do not require custom drivers. As a result, system design is simplified while engineers can drive the switches using technology they are already familiar with (i.e., drivers and packages). Other factors affecting AES’ selection included Transphorm’s proven reliability—which is underscored by its GaN platform earning both a JEDEC qualification and AEC-Q101 qualification at 175°C.
“Transphorm designed its GaN devices to enable designers, not challenge them,” said Philip Zuk, VP of Worldwide Technical Marketing and NA Sales, Transphorm, “Our two-switch normally-off GaN devices come in standard packages and require minimal supporting circuitry to drive them, which reduces the overall system size, increases reliability, and simplifies design. It’s crucial to us that our customers can come to market quickly with a product they have confidence in. We’re honored to be AES’ GaN supplier of record and are proud that they appreciate the work we’ve done to bring the benefits of GaN technology to the masses.”
AES’ PS250X and PS6120 power supplies are currently shipping.
About AES
Headquartered in Germany, AES Aircraft Elektro/Elektronik System GmbH is an international company comprised of over 160 highly skilled employees, serving customers in the aviation, space, and maritime industries. AES’ portfolio includes, but is not limited to, aircraft cabins electronics, comprehensive electrical engineering services, electronic design, and certification services.
About Transphorm
Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power applications. Holding the largest IP portfolio (1000+ patents), Transphorm produces the industry’s first JEDEC and only AEC-Q101 qualified GaN FETs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005252/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
